By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced




Founder: Joshua Boger

CEO: Jeffrey Leiden

CMO (Medical): Jeffrey Chodakewitz

CFO: Ian Smith

CSO (Scientific): David Altshuler


Please click here for clinical trial information.


Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Vertex (VRTX) Announces Nine Presentations Of Data On ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) At The European Cystic Fibrosis Society (ECFS) Conference 6/12/2017 7:11:42 AM
Vertex (VRTX) Names Dr. Alan Garber, Provost Of Harvard, To Its Board Of Directors 6/9/2017 7:04:51 AM
3 Biotechs That May Be Gearing Up For A Vertex (VRTX)-Like Run 6/9/2017 6:27:21 AM
Vertex (VRTX) Announces Nine Presentations Of Data On ORKAMBI (Lumacaftor/Ivacaftor) And KALYDECO (Ivacaftor) At The European Cystic Fibrosis Society (ECFS) Conference 6/9/2017 6:23:25 AM
Vertex (VRTX) Announces Long-Term Reimbursement Agreement With The Republic Of Ireland For ORKAMBI (Lumacaftor/Ivacaftor), KALYDECO(Ivacaftor) And Future Cystic Fibrosis Medicines 6/1/2017 11:42:04 AM
Concert Pharma (CNCE) Announces Shareholder Approval Of CTP-656 Asset Purchase Agreement With Vertex (VRTX) 5/24/2017 9:17:40 AM
Maxor Selected As Limited Distribution Provider Of Orkambi And Kalydeco 5/19/2017 12:11:14 PM
Vertex (VRTX) Awards 40 Scholarships Totaling $200,000 To People Living With Cystic Fibrosis And Their Immediate Family Members 5/19/2017 6:24:00 AM
Vertex (VRTX) Release: FDA Approves KALYDECO (Ivacaftor) For More Than 900 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function Mutations 5/18/2017 8:56:37 AM
X-Chem And Vertex (VRTX) Enter Into Multi-Target Genetic Disease Collaboration 5/16/2017 6:30:21 AM